Pharma Journalist 8791 posts 0 comments

Roche announced that the phase III MINISTONE-2 study showed that one-dose Xofluza (baloxavir marboxil) was a well-tolerated and effective potential treatment for flu in otherwise…
Read More...

Novartis announced results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto (sacubitril/valsartan) in patients with…
Read More...

BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, announced completion of construction of a new state-of-the-art manufacturing facility. The new…
Read More...

LabCorp announced that its Covance Drug Development business has launched a laboratory solution within its functional service provider (FSPx) offering. Covance has been offering FSP…
Read More...

Novartis announced full results from its global Phase III PARAGON-HF study, investigating the efficacy and safety of Entresto (sacubitril/valsartan) versus the active comparator…
Read More...

At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from…
Read More...

SMi Reports: Mike Page, Executive Director Global Regulatory Affairs Portfolio Products at Alexion Pharmaceuticals invites heads of medical affairs and all who are interested to SMi’s…
Read More...

Ajinomoto Bio-Pharma Services announced its intention to purchase the remaining 50 percent ownership interest in its Visakhapatnam, India joint venture, Granules OmniChem Private…
Read More...

Roche announced that the European Commission has approved Tecentriq (atezolizumab) plus chemotherapy (Abraxane ) for the treatment of adult patients with unresectable locally advanced…
Read More...

AstraZeneca announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint,…
Read More...